Skip to main content
OpenTrials
Completed

NCT Number: NCT04948216

Management and Healthcare Utilization of Patients With Chronic Airway Disease During the COVID-19 Epidemic

During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the influencing factors during the COVID-19 epidemic.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Asthma Bronchial Diseases Chronic Disease Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

About this study

During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the relevant factors during the COVID-19 epidemic. Using cross-sectional research methods, telephone interviews and questionnaire surveys were used to investigate the management and healthcare utilization of patients with chronic airway disease （COPD and asthma）during the COVID-19 epidemic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COPD patients and asthma patients in the Chronic Airway Disease Database in Peking University Third Hospital.

Exclusion criteria

  • Refusal to participate in this study; cognitive dysfunction.

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

  1. Respiratory symptoms

    Time frame: through study completion, an average of 2 week.

    COPD Assessment Test (CAT)

  2. Frequency of exacerbation during the COVID-19 epidemic

    Time frame: through study completion, an average of 2 week.

    Frequency of exacerbation during the COVID-19 epidemic

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

Management and Healthcare Utilization of Patients With COPD and Asthma During the COVID-19 Epidemic in Beijing

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 1, 2021
Registry last updated
Jul 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.